Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release

Affiliations

¹ University Medical Centre Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Frankfurt am Main, Germany.
² Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany.
³ Department of Psychiatry, University of Münster, Münster, Germany.
⁴ Department of Psychiatry, The University of Melbourne, Melbourne, Australia.
⁵ Johnson & Johnson, Beerse, Belgium.
⁶ Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
⁷ GAMIAN-Europe, Brussels, Belgium.
⁸ Independent consultant, Leipzig, Germany.
⁹ Johnson & Johnson, Neuss, Germany.
¹⁰ Institute of Neuroscience, University of Barcelona, Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Spain.

Andreas Reif et al. Eur Psychiatry. 2025.

. 2025 Oct 14:1-31.

doi: 10.1192/j.eurpsy.2025.10123. Online ahead of print.

¹ University Medical Centre Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Frankfurt am Main, Germany.
² Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany.
³ Department of Psychiatry, University of Münster, Münster, Germany.
⁴ Department of Psychiatry, The University of Melbourne, Melbourne, Australia.
⁵ Johnson & Johnson, Beerse, Belgium.
⁶ Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
⁷ GAMIAN-Europe, Brussels, Belgium.
⁸ Independent consultant, Leipzig, Germany.
⁹ Johnson & Johnson, Neuss, Germany.
¹⁰ Institute of Neuroscience, University of Barcelona, Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Spain.

No abstract available

Keywords: esketamine; health-related quality of life; quetiapine; treatment resistant depression.

LinkOut - more resources